NRx Pharmaceuticals Has Obtained Up To Approximately $16M In Convertible Debt Financing From An Institutional Investor To Support The 2024 New Drug Application Filing Its Two Lead Products, NRX-100 And NRX-101 And To Retire Existing Debt From...
NRx Pharmaceuticals Has Obtained Up To Approximately $16M In Convertible Debt Financing From An Institutional Investor To Support The 2024 New Drug Application Filing Its Two Lead Products, NRX-100 And NRX-101 And To Retire Existing Debt From...
NRx Pharmaceuticals已經從機構投資者獲得約1600萬的可轉換債務融資，以支持其兩個主導產品NRX-100和NRX-101的2024年新藥申請和償還現有債務。
NRx Pharmaceuticals Has Obtained Up To Approximately $16M In Convertible Debt Financing From An Institutional Investor To Support The 2024 New Drug Application Filing Its Two Lead Products, NRX-100 And NRX-101 And To Retire Existing Debt From Streeterville Capital
NRx製藥已從機構投資者獲得了約1600萬美元的可轉換債務融資，以支持其兩個主導產品NRX-100和NRX-101的2024年新藥申請提交，並清償Streeterville Capital的現有債務。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。